| Objective To investigate the efficacy and safety of venlafaxine in drug genetic testing for patients with depression, and to provide references for individualized medication. Methods A total of 66 patients who met the diagnostic criteria for depressive episode in the International Classification of Diseases, tenth edition (ICD-10) were included in the study. Patients who were recommended to be treated with venlafaxine in the test report were divided into study group (n=32), and those who were decided to be treated with venlafaxine by doctors after consultation with patients were divided into control group (n=34). Hamilton Depression Scale-24 item (HAMD-24) was used before treatment and at the end of 2nd, 4th, 6th and 8th weekend of treatment to evaluate the clinical efficacy. before treatment and at the end of 8th weekend of treatment, Sheehan Disability Scale (SDS) was used to evaluate the social function of patients. After treatment, Treatment Emergent Symptom Scale (TESS) was used to evaluate the incidence of adverse reactions. Results At the end of 4th, 6th and 8th weekend of treatment, HAMD-24 scores in the study group were all lower than those in the control group, and the differences were statistically significant (t=2.344, 4.316, 5.760, P<0.05 or 0.01). At the end of 8 weeks of treatment, the SDS score of the study group was lower than that of the control group, the difference was statistically significant (t=2.173, P<0.05). The incidence of adverse reactions in the study group was lower than that in the control group, the difference was statistically significant (χ2=5.720, P<0.05). Conclusion Using venlafaxine in the treatment of depression based on pharmacogenomic testing can improve depression in patients with good safety. |